Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Sponsor: The University of Texas at Arlington
This PHASE4 trial investigates Chronic Kidney Diseases and is currently actively recruiting participants. The University of Texas at Arlington leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE4
-
Sep 2024 — Jul 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE4
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE4
▶ Show 7 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Recruiting PHASE4
-
Sep 2021 — Jun 2022 [monthly]
Recruiting PHASE4
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jul 2020 — Dec 2020 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Jul 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Texas at Arlington
- University of Texas, Southwestern Medical Center at Dallas
For direct contact, visit the study record on ClinicalTrials.gov .